Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Trail of Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for the Treatment of Metastatic Lung Cancer: SBRT Sensitization of the Programmed Death-1 (PD-1) Effect

NCT03825510 is registered in ClinicalTrials.gov with Crozer-Keystone Health System as lead sponsor.

NCT NCT03825510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03825510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Trail of Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for the Treatment of Metastatic Lung Cancer: SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
Lead sponsor
Crozer-Keystone Health System
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2017
Completion date
March 8, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nonsmall cell lung cancer, non small cell lung cancer